Skip to main content
Skip to footer

Using TCS 5I Model to Strengthen Drug Safety and Make it Patient-Centric

Debashis Ghosh

President – Life Sciences, Healthcare, Government and Energy Business Group, TCS

Amit Saxena

Head - Strategic Initiatives, Life Sciences, TCS

Dr. Rajgopal Srinivasan

Prinicipal Scientist, Head of Bio-IT R&D Innovation Labs, Hyderabad, TCS

You have these already downloaded

We have sent you a copy of the report to your email again.

TCS 5i model future proofs the drug safety sector to service patients better.

TCS 5i framework re-imagines the drug safety landscape and presents a unified approach to address the challenges in following way: it integrates insights, inquires and works with R&D to gain relevant information, identifies safety concerns, improves show risks are addressed, and informs by devising a communication strategy.

Scientific advancements & digital technologies have created new opportunities for modernizing drug safety.

Related reading

Investigating Drug Interaction Under Hypoxia to Treat COVID-19

White Paper | 15 Mar 2023

Leveraging TCS Real World Evidence Services for Tangible Outcomes

Solution | 01 Mar 2023

The Emerging Trends of Microneedles for Insulin Delivery

White Paper | 28 Feb 2023

Metaverse in Healthcare: Realizing Business Value and Opportunities

White Paper | 18 Jan 2023

Transformation starts here

Integrated ecosystems are key to better patient outcomes.

Talk to our experts

Find out more